We elected to use a 90% cutoff to distinguish cases with reduced HLA-DRA expression on the basis that this was the most predictive of outcome and would identify patients where tumor cells might be capable of escaping immune surveillance. This evidence concerns the gene HLA-DRA and neoplasm.